Medicine
from24/7 Wall St.
20 hours agoSarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
Sarepta Therapeutics' stock surged 20% after releasing promising clinical data for two siRNA programs targeting rare neuromuscular diseases.